The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.

In phase 3 clinical trials, tildrakizumab treatment was associated with significantly higher ACR20 response rates at week 24 compared with placebo.

Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at ...

Failure to respond to targeted disease-modifying antirheumatic drugs (tsDMARDs) for psoriatic arthritis occurs at an incident rate of about 0.35 per person-year. An observational cohort of 591 ...

There are many treatment options for psoriatic arthritis (PsA), and EULAR—The European Alliance of Associations for Rheumatology—recommends a practical and progressive approach to management based on ...

Psoriatic arthritis represents one of the more challenging inflammatory conditions in rheumatology, affecting approximately 20% of individuals with psoriasis while sometimes developing independently ...

Psoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both conditions may mean special attention should be given to selecting optimal treatment, according to a study ...

Susan Goodman, MD, from the Hospital for Special Surgery in New York City, talks through what the latest research says and how making certain adjustments may help optimize care for these patients.

Joni Kazantzis was diagnosed with psoriasis at 15 and received a psoriatic arthritis diagnosis during the pandemic. She created a blog and social platform to offer the guidance she once ...